company background image
VLS

Vita Life SciencesASX:VLS Stock Report

Market Cap

AU$85.3m

7D

3.0%

1Y

60.9%

Updated

18 Oct, 2021

Data

Company Financials
VLS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance6/6
Financial Health6/6
Dividends3/6

VLS Overview

Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, distribution, and sale of vitamins and supplements.

Price History & Performance

Summary of all time highs, changes and price drops for Vita Life Sciences
Historical stock prices
Current Share PriceAU$1.55
52 Week HighAU$0.84
52 Week LowAU$1.62
Beta0.13
1 Month Change26.64%
3 Month Change44.39%
1 Year Change60.94%
3 Year Change60.94%
5 Year Change3.00%
Change since IPO808.82%

Recent News & Updates

Aug 24
Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Shareholder Returns

VLSAU PharmaceuticalsAU Market
7D3.0%0.04%0.9%
1Y60.9%-2.4%20.2%

Return vs Industry: VLS exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: VLS exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is VLS's price volatile compared to industry and market?
VLS volatility
VLS Beta0.13
Industry Beta1.3
Market Beta1

Stable Share Price: VLS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: VLS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1947n/aAndrew O'Keefehttps://www.vitalifesciences.com

Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, distribution, and sale of vitamins and supplements. It offers a range of supplements, vitamins, minerals, herbs, and superfoods. The company markets its products through pharmacies and health food stores under the Herbs of Gold, VitaHealth, VitaScience, and VitaLife brands.

Vita Life Sciences Fundamentals Summary

How do Vita Life Sciences's earnings and revenue compare to its market cap?
VLS fundamental statistics
Market CapAU$85.26m
Earnings (TTM)AU$6.72m
Revenue (TTM)AU$50.19m

12.7x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VLS income statement (TTM)
RevenueAU$50.19m
Cost of RevenueAU$19.20m
Gross ProfitAU$30.98m
ExpensesAU$24.26m
EarningsAU$6.72m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.12
Gross Margin61.73%
Net Profit Margin13.38%
Debt/Equity Ratio0%

How did VLS perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

43%

Payout Ratio

Valuation

Is Vita Life Sciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VLS (A$1.55) is trading below our estimate of fair value (A$3.27)

Significantly Below Fair Value: VLS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VLS is good value based on its PE Ratio (12.7x) compared to the Oceanic Pharmaceuticals industry average (45x).

PE vs Market: VLS is good value based on its PE Ratio (12.7x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VLS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VLS is good value based on its PB Ratio (3.1x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is Vita Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vita Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Vita Life Sciences performed over the past 5 years?

13.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VLS has high quality earnings.

Growing Profit Margin: VLS's current net profit margins (13.4%) are higher than last year (11.3%).


Past Earnings Growth Analysis

Earnings Trend: VLS's earnings have grown by 13.4% per year over the past 5 years.

Accelerating Growth: VLS's earnings growth over the past year (32.6%) exceeds its 5-year average (13.4% per year).

Earnings vs Industry: VLS earnings growth over the past year (32.6%) exceeded the Pharmaceuticals industry 17.4%.


Return on Equity

High ROE: VLS's Return on Equity (23.9%) is considered high.


Financial Health

How is Vita Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: VLS's short term assets (A$30.8M) exceed its short term liabilities (A$13.4M).

Long Term Liabilities: VLS's short term assets (A$30.8M) exceed its long term liabilities (A$388.0K).


Debt to Equity History and Analysis

Debt Level: VLS is debt free.

Reducing Debt: VLS has no debt compared to 5 years ago when its debt to equity ratio was 12%.

Debt Coverage: VLS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: VLS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Vita Life Sciences's current dividend yield, its reliability and sustainability?

3.56%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: VLS's dividend (3.56%) is higher than the bottom 25% of dividend payers in the Australian market (2.27%).

High Dividend: VLS's dividend (3.56%) is low compared to the top 25% of dividend payers in the Australian market (5.32%).


Stability and Growth of Payments

Stable Dividend: VLS's dividend payments have been volatile in the past 10 years.

Growing Dividend: VLS's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (43.1%), VLS's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Andrew O'Keefe

4.75yrs

Tenure

AU$509,988

Compensation

Mr. Andrew O'Keefe has been Managing Director of Vita Life Sciences Limited since January 1, 2017 serves as its Director. Mr. O'Keefe served as Acting Managing Director of Vita Life Sciences Limited since...


CEO Compensation Analysis

Compensation vs Market: Andrew's total compensation ($USD378.53K) is about average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: VLS's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: VLS's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.


Top Shareholders

Company Information

Vita Life Sciences Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Vita Life Sciences Limited
  • Ticker: VLS
  • Exchange: ASX
  • Founded: 1947
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$85.265m
  • Shares outstanding: 55.19m
  • Website: https://www.vitalifesciences.com

Location

  • Vita Life Sciences Limited
  • Bath Road
  • Unit 1/102
  • Kirrawee
  • New South Wales
  • 2232
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:11
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.